Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15630945 | 1.00 | MEN1 (0.54) | MEN1MAPTKMT2AGRM5ADRB1 | |
| SCHEMBL2293083 | 1.00 | MEN1 (0.54) | MEN1MAPTKMT2AGRM5ADRB1 | |
| SCHEMBL2294859 | 0.95 | GFER (0.56) | MEN1MAPTKMT2AGRM5DPP4 | |
| SCHEMBL12378355 | 0.92 | ADRB1 (0.56) | MAPTADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL2296038 | 0.91 | CACNA2D1 (0.51) | MEN1KMT2AADRB1HTR2AHTR2B | |
| SCHEMBL12378470 | 0.90 | ME2 (0.55) | MAPTADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL2288557 | 0.90 | ME2 (0.55) | MAPTADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL12378468 | 0.90 | ME2 (0.55) | MAPTADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL12378457 | 0.90 | ADRB1 (0.54) | MEN1MAPTKMT2AADRB1HTR2A | |
| SCHEMBL12378461 | 0.89 | GFER (0.54) | MAPTGRM5ADRB1HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238633-B2 | Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-19 | — | — | US | disclosed |
| US-9238633-B2 | Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-19 | — | — | US | disclosed |
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
| US-8648083-B2 | Method of treating diabetic hyperlipidemia or hyperlipidemia with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-02-11 | — | — | US | disclosed |
| US-8648083-B2 | Method of treating diabetic hyperlipidemia or hyperlipidemia with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-02-11 | — | — | US | disclosed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20130131081-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131081-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-05-23 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| WO-2008140198-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO., LTD. (KR) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, OPRD1, OPRL1 | MEN1 4789/4885MAPT 3315/4885KMT2A 1354/4885 |
| US-20130131081-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | LIPG, CETP, GPR119 | MEN1 4779/4885MAPT 1539/4885KMT2A 3036/4885 |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, CNR2, CNR1 | MEN1 4771/4885MAPT 3022/4885KMT2A 1206/4885 |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | HTR5A, OPRL1, HDAC3 | MEN1 4723/4885MAPT 2882/4885KMT2A 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.